unknown by unknown
A prospective database identified 77 patients who had preoperative 
radiotherapy for rectal cancer (2500 cGy in 5 consecutive daily fractions in 
the week preceeding surgery) There were 4 exclusions, 1 neuroendocrine 
tumour and 3 with incomplete records. For the resulting 73 patients data 
concerning patient demographics, staging, operation, pathology, morbidity 
and mortality were recorded by a retrospective case note review. 
The median age was 69 years (interquartile (IQ) range 61 ￿ 74) and 18 were 
female. The median post-operative follow up was 518 days (IQ range 254 ￿ 
976). Preoperative radiographic imaging was undertaken in 65/73 patients 44 
had a CT scan, 21 a MR scan. In 31 scans there was evidence of perirectal 
infiltration. Examination under anaesthetic prior to definitive surgery was 
performed in 32 patients. 
In 63/72 operations were performed with curative intent, in 8 the operation 
was deemed to be palliative in one case the intent was not documented and 1 
patient was not operated on. The reasons for palliation were previously 
undetected liver metastases at laparotomy in 5, in 1 the primary lesion was 
deemed irresectable, in 1 the primary lesion was locally invasive and in 1 
there were irresectable lymph node metastases. Detailed pathology was 
available in 53 cases. The lateral margin was involved microscopically in 2 
patients of whom 1 developed a local recurrence. 
Eighteen patients experienced early morbidity, 3 anastomotic leaks, 8 delayed 
wound healing and 4 urinary retentions, and 1 patient experienced 
radionecrosis of a perineal wound requiring plastic surgical reconstruction. 
Local recurrence occurred in 4/72 (5.6%) patients at a median of 354 days 
post operation (range 74 ￿ 1716); for 2 of these patients surgery had been 
palliative giving a local recurrence rate of 2/63 (3.2%) for those having 
potentially curative operations. Distant metatases occurred in 14 patients, 5 at 
laparotomy, 9 developed metastases at median of 493 days post operation (IQ 
range 260 ￿ 573). To date there have been 15 deaths at a median survival of 
407 days (IQ range 167 ￿ 928), 1 death from locally recurrent disease, 12 
from metastatic colorectal cancer and 2 non-cancer deaths (one from 
postoperative complications). 
In conclusion the results of our selective policy indicate a low local 
recurrence rate for a high risk cohort of patients. The importance of optimal 
preoperative staging in reducing the number of patients with metastatic 
disease receiving such treatment is emphasised. 
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CHEMO-RADIOTHERAPY IN THE MANAGEMENT OF 
UNRESECTABLE CHOLANGIOCARCINOMA. THE MIDDLESEX 
HOSPITAL EXPERIENCE 1994-2002; 
S.G. Russell, R. Hughes*, S. J. Rogers, M.Beresford and M.F.Spittle. 
Meyerstein Institute of Oncology, Middlesex Hospital W1T 8AA, 
Introduction.  Cisplatin-based chemo-radiotherapy (chemo-RT) has been 
advocated as the treatment of choice in the management of a number of 
malignancies. Its role in the treatment of unresectable cholangiocarcinoma 
remains undefined. Acute toxicity is a serious concern and may lead to delays 
in RT which could offset  any benefit from the addition of chemotherapy. 
Aims. We reviewed the management of patients with inoperable 
cholangiocarcinoma treated between 1994 and 2002. Of primary interest 
were overall survival from time of diagnosis, length of inpatient stay, 
treatment related acute toxicity and delays in treatment. 
Methods. The case-notes of forty-one consecutive inoperable 
cholangiocarcinoma patients were examined. All patients received external 
beam radiotherapy to the site of disease, either 45 Gy in 25 daily fractions 
over 5 weeks or 30Gy in 10 daily fractions . Sixteen patients received 
concurrent chemotherapy. Chemotherapy consisted of 3-weekly cisplatin 
100mg day 1 and 3-weekly 5-fluorouracil 750mg days 1 to 3. 
Results Of the 41 patients, 28 were male (68%) and 13 female (32%). The 
average age at diagnosis was 60.4 years (32-77). 33 patients (77%) had 
histologically proven cholangiocarcinoma. All patients had undergone 
palliative stenting procedures prior to definitive therapy. The median survival 
was 14 months (2-31 months) in the chemo-RT group compared with 8 (1-30 
months) in the RT alone group. Toxicities in the two groups were similar. 
Only 1 patient had a grade 3 toxicity of any system, having developed 
neutropaenic pyrexia following their second cycle of chemotherapy. None of 
the 16 patients who completed the prescribed course of external beam RT 
experienced any delays in RT.  
Conclusion: Chemo-RT for the treatment of unresectable cholangiocarcinoma 
is a well tolerated technique without significant additional toxicity and does 
not result in delays in RT. The overall survival was greater in the combined 
modality group. Performance status was a selection criterion for chemo-RT. 
This is in itself a good prognostic factor and may therefore have contributed 
to the better outcome seen in this group. The cost of chemo-RT and increased 
time spent in hospital however raise doubts over its routine use.  Further 
randomised data is required. 
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COLORECTAL CANCER: IDENTIFICATION OF 
DIFFERENTIALLY EXPRESSED PROTEINS USING A 
PROTEOMICS APPROACH 
L.C. Lawrie
*1,2, G.I. Murray
2, Departments of 
1Molecular & Cell Biology, 
2Dept. of Pathology, University of Aberdeen, Aberdeen, UK. 
Colorectal cancer is one of the most common malignancies in the UK with 
30, 000 new cases and 20, 000 deaths from the disease each year. To improve 
prognosis from colorectal cancer there is an urgent need to identify molecular 
markers to detect the disease at an early stage where even current treatment 
regimes would be much more effective. Prognostic markers for colorectal 
cancer are also vitally required as two tumours may be histologically 
classified as being at the same stage but these tumours may then go on to 
have very different outcomes in terms of patient survival. New prognostic 
markers could predict how a particular tumour is likely to respond to 
treatment, thus ensuring that patients receive therapy individually tailored to 
their own requirements. Proteomics is a powerful analytical technique which 
can help identify diagnostic and prognostic markers for colon cancer by 
comparing differences in protein expression profiles from normal or tumour 
tissues.  Two-dimensional gel electrophoresis is performed to produce protein 
expression profiles from fresh frozen paired samples of normal and tumour 
tissue. Image analysis of these gels identify those proteins which show 
differential expression, these proteins are likely to be associated with the 
disease process and can be identified through mass spectrometry and 
database searching. We have optimised conditions for solubilising the colon 
tissue and have produced 2D-gel protein expression profiles of patient 
matched samples of normal and colon tumour tissue, initially selecting 
tumours from patients with an advanced stage of the disease. The protein 
expression profiles obtained from the normal and tumour tissue were 
reproducible not only when replicate samples were taken from the same 
patient but also when these profiles were compared with samples taken from 
other patients. Proteins which showed differential expression were excised 
from the gel and identified through mass spectrometry and database 
searching. Some of the proteins which showed increased expression in the 
tumour samples were found to be proteins which are already known to be 
associated with colorectal cancer progression. We have also identified several 
novel proteins which are consistently upregulated in the tumour samples. 
These proteins may be useful as molecular markers for colorectal cancer 
which could be used to screen patients to detect the disease at an early stage, 
or as prognostic indicators to determine the likely course of the disease. A 
possible further application may be to use the proteins which have been 
differentially expressed as therapeutic drug targets for the development of 
new chemotherapeutic agents. 
Reference 
Lawrie LC, Fothergill JE, Murray GI., Spot the differences: proteomics in 
cancer research. The Lancet Oncology 2001; 2: 270-77. 
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OUTCOMES OF THE TREATMENT OF HIGH GRADE GLIOMAS - 
THE CAMBRIDGE EXPERIENCE.
K.J. Waite*, N.G Burnet and R.V. Bulusu. Dept of Oncology, Box 193, 
Addenbrooke￿s Hospital, Cambridge, CB2 2QQ. 
Background. High grade gliomas have a very poor median survival despite 
radical treatment. We present the results of 317 adult patients who presented 
to our unit between October 1996 and August 2001. 
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determined by their performance status and age. 158 patients who were fit, 
with a WHO performance status of 0-1 and aged less than 70 received 
treatment with a radical intent. Radical radiotherapy was CT planned and a 
dose of 60Gy in 30 fractions over 6 weeks was prescribed for grade 4 lesions, 
54Gy in 30 fractions over 6 weeks for grade 3 lesions, both using 6-8mv 
photons. 108 patients aged 70 or more and/or with a WHO performance 
status of 2 or more were treated with palliative intent. Palliative radiotherapy 
was planned orthogonally using parallel opposed lateral fields and was 
prescribed to a dose of 30Gy in 6 fractions over 2 weeks. 51 patients with 
poor performance status received best supportive care alone. Survival was 
calculated from the date of diagnosis. 
Results. Those patients who received radical radiotherapy had a median 
survival of 315 days; those with Grade 3 tumours had a median survival of 
1150 days compared to those with grade 4 tumours (glioblastoma 
multiforme) who had a median survival of 279 days. In 135 patients radical 
radiotherapy was commenced in a mean of 31.2 days (95% CI 28.1-34.2 
days) from being requested. Those patients who received palliative 
radiotherapy had a median survival of 140 days. In 76 patients palliative 
radiotherapy was commenced in a mean of 17.6 days from being requested 
(95%CI 15.2-20 days). Palliative radiotherapy was therefore completed 6 
weeks before radical radiotherapy. Those patients who did not receive 
radiotherapy had a median survival of 43 days. 
Conclusions.  Our results are very similar to other published series and 
emphasize the need to carefully select patients prior to treatment. The 
difference in completion time between radical and palliative radiotherapy 
may be important. Outcome in poor performance patients as expected was 
very poor. There is a need for alternative strategies to be explored in the 
treatment of these tumours. 
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IS IT WORTH REIRRADIATING PRIMARY BRAIN TUMOURS? 
CAMBRIDGE EXPERIENCE 
Y.L.Rimmer* N.G. Burnet 
Department of Clinical Oncology, Addenbrookes Hospital, Cambridge. CB2 
2QQ 
Purpose
The aims were to determine overall survival and progression free survival 
following reirradiation of malignant glioma, and to assess safety and 
predictability of outcome. 
Methods
Eleven patients with a median age of 45.8 years received reirradiation for 
recurrent gliomas (1997-2001). Eligibility for selection was a performance 
status of 0-1, a minimum interval of one year from previous treatment and 
small volume disease. The median interval between the two treatments was 
48 months. External beam radiotherapy for the primary treatments was 
delivered with a variety of methods whilst the reirradiation treatment used a 
conformal plan with tight margins. The median radiation doses of the first 
and second treatments were 54Gy and 45 Gy, respectively.  The median 
cumulative biological effective dose (BED) was 181.4 (a/b=2). 
Results
Subsequent to retreatment, two patients currently remain alive and well with 
no evidence of recurrence after 41.4 and 23.2 months respectively.The 
median progression free survival (PFS) of the remaining nine patients was 
6.9 months.The six patients who have died had a median overall survival 
(OS) from completion of retreatment of 19.6 months. Three patients are 
currently receiving chemotherapy after relapse of disease.Seven patients had 
surgical intervention at the time of relapse, either biopsy or debulking of 
tumour. Histological grading remained the same as that on initial presentation 
in four patients whilst three patients had transformed from grade 3 to grade 4 
disease. 
Histological grade was not a predictor of relapse. At the time of recurrence 
the two patients who had grade 2 disease are alive and well but the five 
patients who had grade 3 disease had a median PFS of 6.9 months and the 
four patients who had grade 4 disease had a median PFS of 9.2 months. 
Minimal acute and no late side affects occurred and quality of life remained 
good even after relapse in the majority of patients. 
Conclusion 
These results support the use of reirradiation in appropriately selected 
patients with all grades of recurrent glioma. A median PFS of 6.9 months was 
demonstrated but more interestingly OS determined from the end of the 
second radiotherapy treatment was 19.6 months. 
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AN AUDIT OF THE USE OF DOSE VOLUME HISTOGRAMS 
(DVH￿s) IN PREDICTING RATES OF RADIATION PNEUMONITIS 
IN PATIENTS TREATED WITH RADIOTHERAPY TO THE LUNGS  
S J Clenton*   M Q Hatton   P M Fisher  P Kirkbride,  All Weston Park 
Hospital, Sheffield 
AIM
 Rates of pneumonitis can be correlated to the volume of lung irradiated using 
3D treatment planning and DVH￿s.  (1) In Sheffield treatment schedules for 
thoracic irradiation do not use the convention of 1.8-2 Gy fraction size.   
However, we have used the experience of Graham et al as a guide to amount 
of lung irradiated to greater than 20 Gy.  This audit aimed to assess if the 
rates of radiation pneumonitis for our non-conventional fraction sizes are in 
keeping with those described by Graham et al.  
METHOD
This audit has retrospectively reviewed all 3D CT planned thoracic 
radiotherapy treatments between January 1999 and July 2001.  The notes of 
patients who received doses greater than 36 Gy using an isocentric technique 
were reviewed for evidence of radiation pneumonitis using the RTOG acute 
lung morbidity scale.  (2)   
RESULTS
119 patients were identified and DVH￿s showed the amount of lung receiving 
greater than 20 Gy varied from 6% to 51%. 44 were treated with CHART, 48 
with radical radiotherapy 54/55Gy in 20 fractions and the remainder received 
high dose palliative treatment.  (Ranging from 36 Gy in 12 fractions to 50 Gy 
in 20 fractions).  Using the RTOG pneumonitis score, 70 score 0, 27 score 1, 
4 score 2, 16 score 3 and 2 score 4.  Those with evidence of pneumonitis 
appear to have had a higher percentage of lung treated to greater than 20 Gy.  
CONCLUSIONS
The pneumonitis score appeared to be an easy to apply and relevant scoring 
system which correlated well with descriptions in notes. The rates of 
pneumonitis were low in the patients treated and appear compatible with the 
rates described by Graham et al.  
REFERENCES
(1) M V Graham et al, 1999,  Int. J. Radiation Oncology Biol. Phys., Vol 45,  
p 323. 
(2)R W Byhardt et al, 1993, Int. J. Radiation Oncology Biol. Phys., Vol 27, 
p537.
P72 
SOMNOLENCE SYNDROME FOLLOWING PROPHYLACTIC 
CRANIAL IRRADIATION IN LIMITED STAGE SMALL CELL 
LUNG CANCER. 
H.J.H. Taylor*, L.Vini 
Royal Marsden Hospital, Sutton, Surrey  SM2 5PT, UK. 
Introduction: Prophylactic cranial irradiation (PCI) has been shown to offer a 
small yet significant survival advantage to those patients with limited stage 
small cell lung cancer (SCLC) achieving a complete response following 
combination chemotherapy„. However, quality of life can be adversely 
affected by the radiation induced somnolence syndrome, which affects up to 
80% of those with primary brain tumours treated with high dose 
radiotherapy†. 
Aim: To investigate the incidence and duration of somnolence in patients 
with limited stage SCLC who receive PCI following combination 
chemotherapy. 
Method: Between July 2000 and May 2001, 18 patients (age range 38 ￿ 75 
years, mean 57) with limited stage SCLC achieved complete response 
following chemotherapy and were referred for both consolidation thoracic 
radiotherapy and PCI. All 18 received consolidation thoracic radiotherapy to 
the site of disease at presentation (40Gy in 15# over 3 weeks using a 3 field 
CT planned technique) and PCI (30Gy in 10# over 2 weeks using standard 
parallel opposed technique). Treatment related toxicity both during 
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recorded, particularly symptoms compatible with somnolence syndrome. 
Results: All patients complained of lethargy during radiotherapy with 8 
(44%) requiring regular antiemetics and 3 (16%) starting dexamethasone. 4 
weeks following radiotherapy 14 (78%) admitted to symptoms compatible 
with radiation induced somnolence syndrome, with 8 (44%) taking 
dexamethasone and 6  (33%) regular antiemetics. The mean duration of 
lethargy was 3 months (range: 2 weeks to 8 months). In this small series there 
were no significant predictive factors for prolonged lethargy following 
treatment. 
Conclusion. In this series 78% of patients developed symptoms compatible 
with the somnolence syndrome following PCI. Further prospective quality of 
life data is needed. Possible changes in practice include a reduction in 
radiotherapy dose or the use of prophylactic steroids. 
„ AupØrin A, Arriagada R, Pignon J-P et al. 1999. N Engl J Med; 341:476 
† Faithfull S and Brada M. 1998. Clin Oncol; 10:250 
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THE  FACILITATION OF ROUTINE CARDIAC SHEILDING IN 
THE RADIOTHERAPY TREATMENT OF EARLY BREAST 
CANCER BY INTENSITY MODULATED RADIOTHERAPY (IMRT)   
Le Vay JH*
1, Poynter AJ
1, Mackenzie LM
1.
Suffolk Oncology Centre
1, Ipswich Hospital, Ipswich.UK. 
AIM: To investigate whether the acquisition of the facility to use Intensity 
Modulated Radiotherapy (IMRT) would allow the use of Multi-Leaf 
Collimation to allow easy and routine cardiac shielding in the treatment of 
patients with early breast cancer.  
METHODS: Cardiac toxicity has been shown to be a cause of long term 
morbidity and mortality after  Adjuvant Radiotherapy in the treatment of 
patients with early Breast cancer. This has been predominately based on 
patients treated from an era when precise localisation of treatment fields was 
more difficult and the Internal mammary chain often treated. (And hence in 
left sided tumors a significant portion of underlying myocardium was 
included.) However even with modern CT planned techniques a significant 
portion of the apex of the heart will be included in the breast tangential fields. 
The use of a custom made block to shield this portion of the heart is for most 
centres too time consuming for it to be used routinely in such a commonly 
treated condition. Modern  multi-leaf collimation ( MLC) allows easy and 
quick individual shielding from the CT plan; however the use of the  MLC 
precludes the use of a wedge due to the position of the MLC leaves. This 
produces an unacceptable plan.  Ipswich hospital is the Varian reference 
centre for IMRT and the use of IMRT (Electronic compensators) has been 
introduced in to routine use for the treatment of early Breast Cancer 
(following an initial pilot study) due to the improvements seen in dose 
homogeneity. This gave us the option to use the MLC to shield the heart and 
the IMRT  to compensate for the inability to use a wedge. In two patients 
from the previously reported pilot study in whom the heart was in the desired 
treatment fields a conventional 3-D plan with MLC shielding was compared 
to an IMRT plan for the same patient. The plans were compared for adequacy 
of coverage and dose homogeneity across the target tissue.  
RESULTS: The IMRT  (Electronic compensator) plan gave an acceptable 
dose distribution in both patients whereas the non IMRT plan was not 
considered adequate in terms of dose coverage and homogeneity. The 
Volume of target tissue receiving greater than 105% of the prescribed dose 
was reduced by 20% with the IMRT plan. The conventional plan included 
10% less of the desired target tissue within the 95-105% isodose range. In 
both patients the use of IMRT allowed MLC shielding of the heart to be used. 
CONCLUSIONS: IMRT (Electronic compensation) allowed the use of MLC 
shielding of the heart in both cases which was not possible with conventional 
planning. The use of this technique should be considered in the Routine 
Radiotherapy of Early Breast cancer in left sided tumors.  
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LOW DOSE HYPER-RADIOSENSITIVITY - A CLINICAL 
ASSESSMENT 
Dr Jackie Harney*, Dr Susan Short, Prof. Michelle Saunders 
Marie Curie Research Wing, Mount Vernon Hospital, Northwood, 
Middlesex, UK. 
Background and Purpose
Recent laboratory studies have demonstrated that some tumour cells are 
hypersensitive to low doses of radiation (<1Gy/fraction), so called Low Dose 
Hyper-Radiosensitivity (HRS). There is evidence to suggest that this effect 
may also exist in normal tissues, including skin 
The purpose of this study is to establish whether or not HRS can be 
demonstrated in the clinic (a) in normal skin and (b) in metastatic tumour 
nodules, and if it does to determine if there is a therapeutic advantage to 
using multiple low dose treatments. 
Materials and Methods:
Following Ethics Committee approval patients with at least two metastatic 
skin or subcutaneous nodules were recruited to the study. The nodules were 
measured, then consecutively numbered according to volume and 
randomised, in matched pairs, to receive either conventionally fractionated 
radiation treatment (1.5Gy/day), or ultrafractionated radiotherapy (0.5Gy 
TDS with an interfraction gap of 4hrs). Any unpaired nodule received the 
ultrafractionated regimen. Both groups were treated for 12 days (total dose of 
18Gy).  
The tumour nodules were measured in three dimensions on days 0, 4, 8, 12 
and 26 and then 2-4weekly until regrowth occurred. 
At the first five assessments 3mm punch biopsies of normal skin surrounding 
one nodule in each treatment arm were taken, fixed and used to assess 
changes in basal cell density (H&E) and the proliferation markers Cyclin A 
and Ki67 (immunohistochemistry) with dose. 
Results:
To date 5 patients have been accrued, giving a total of 29 nodules (12 pairs). 
Tumour types include leiomyosarcoma, NHL and breast carcinoma. 
The results can be divided into two; the effects on the tumour nodules and the 
effects on the surrounding normal skin.  
Effects on nodules :
In one patient (LMS) metastatic tumour nodules exhibited increased growth 
delay after ultrafactionation (P<0.03). No differences between fractionation 
regimens have been observed, to date, in the other patients. 
Effects on normal skin:
There was no evidence of increased basal cell killing after ultrafractionated 
treatment in any of the patients. An early reduction in basal cell numbers 
(days 5-15) was observed, but this was more marked in the conventional arm.  
Conclusions  
Preliminary data presented here suggest that HRS does occur in human 
tumours at clinically relevant doses. However, the effect was not 
demonstrable in all patients. These data do not support the existence of HRS 
in normal skin when 0.5Gy TDS (with a 4hr gap) is compared to 1.5Gy OD, 
this is contrary to previous data using 0.5Gy once daily.  
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THE EFFECTS OF LOW-DOSE FRACTIONATED RADIATION ON 
SARCOMAS- EXPERIMENTAL AND CLINICAL DATA 
S C Short￿
1, J Harney
1, F Dopson
2, M I Saunders
1
1Marie Curie Research Wing for Oncology, Mount Vernon Cancer Centre, 
Northwood UK 
2The Gray Cancer Institute, Northwood UK 
Background: Increased sensitivity to radiation doses below 1 Gy (Hyper-
radiosensitivity, HRS) has been confirmed in over 50 human tumour cell 
lines in vitro. If the same occurs in tumours in vivo it may be possible to 
exploit this phenomenon clinically by using multiple low-dose treatments in 
tumours that are resistant to conventional radiotherapy.  
Purpose: To examine the response of human sarcoma cell lines to single and 
multiple low-doses of X-rays in vitro and the response of metastatic sarcoma 
nodules irradiated in a clinical protocol using a multiple-low-dose per day 
regime. 
Materials and methods: The clonogenic survival of human sarcoma cells 
(HS633T) was measured in vitro after exposure to single X-ray doses 
between 0.05 and 5 Gy and after multiple 0.4Gy doses. Accurate 
measurement of cell survival was achieved by using a Cell Sorter (FACScan, 
Becton Dickinson, UK) to provide high resolution cell counting. A Pantak 
unit, producing 240kVp Xrays was used to irradiate sorted cells. The 
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equation, which describes enhanced sensitivity at low doses (Induced Repair 
equation). In multiple low dose experiments the relative clonogenic survival 
after 0.4Gy tds and 1.2Gy od daily for 4 days to total doses of 4.8Gy were 
compared. In the clinical study, following local ethical approval, patients 
with at least 2 metastatic skin nodules from primary sarcomas were included 
in a protocol comparing tumour growth delay after 0.5Gy tds or 1.5Gy od for 
12 days (total dose of 18Gy). Lesions were measured in 3 dimensions on 
days 0, 5, 8, 12, 26 then 2-4 weekly. Day 0 measurements were used to pair 
lesions which were then analysed as matched pairs. 
Results: In HS633T cells HRS was demonstrated at doses below 1Gy. In the 
clinical study 10 skin nodules were analysed in 2 patients with metastatic 
leiomyosarcoma. In one patient a significant enhancement of tumour growth 
delay was demonstrated in the low-dose per fraction arm (p=0.003). No 
significant difference between treatments was demonstrated in the 2nd 
patient. 
Conclusion: HRS can be demonstrated in human sarcoma cells after single 
and multiple low-dose irradiations in vitro. Preliminary data suggest that the 
same effect may also occur in metastatic sarcoma deposits but it was not 
demonstrable in all lesions. This heterogeneity may be due to differences in 
HRS expression between tumours or an influence of tumour 
microenvironment. 
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SAFE DELIVERY OF RADIOTHERAPY IN PATIENTS WITH 
IMPLANTED CARDIAC PACEMAKERS. 
S.Santhanam*, S. Bolton, S.Vasanthan, G. Thomas. Dept. of Oncology, 
University Hospitals of Leicester. Leicester. 
BACKGROUND: The increasing elderly population and falling 
cardiovascular mortality is leading to an increase in the number of patients 
with pacemakers (PM) who need radiotherapy (RT). In-vitro studies show 
that the modern multi-programmable PMs utilising the CMOS circuitry can 
be adversely affected by therapeutic radiation and by electromagnetic 
interference from Linear accelerators. (Souliman.1994, Pacing Clin 
Electrophysiol.17: 270; Venselaar. 1985,Radiother Oncol 3: 81). Despite the 
potential risk of catastrophic complications in PM dependent patients, the 
published in-vivo data is sparse regarding the safety of RT delivery in 
patients with PMs. We have set up a database to prospectively collect data on 
patients with PM undergoing RT. 
PATIENTS, METHODS & RESULTS: We report 6 cases who were given 
RT in our department during a 4-month period.(Table). Of these, 5 patients 
were given palliative RT and 1 was given radical RT (2 had RT to the chest, 
2 to Head & Neck (H&N), 1 to axilla and 1 to spleen). The RT fields were 
arranged to minimize the scattered radiation to the PM. The PM of a 95 yr. 
old patient was in the radiation field but she was not PM dependent. The 
patients were monitored with ECGs and pulse oximetry during RT, and PM 
Clinic checks were arranged following completion of RT. None of the 
patients experienced any malfunction of the PM during or after delivery of 
radiotherapy.  
CONCLUSION:  RT can be safely delivered, if direct irradiation of PMs is 
avoided, adequate monitoring is done during and after irradiation, and the 
dose to the PM generator is kept below 2 Gy.  
 Sex  Age  Diagnosis 
Site of RT & 
Prescribed RT Dose / 
Fractions 
Calculated 
Dose to 
PM 
1  M  79  Parotid tumour.  H & N. 64 Gy / 32#   1.3 Gy 
2  F  85  Lymphoma.  H &N.  15 Gy / 5#   0.8 Gy 
3  F  77  Myelofibrosis.  Spleen. 4.5 Gy / 9#  <0.5 Gy 
4  F  95  Breast cancer.  Axilla.  26.7 Gy / 10#   26.7 Gy 
5  M  77  Lung cancer.  Chest.   15 Gy / 10#   0.8 Gy 
6  F  63  Lung cancer.  Chest.   30 Gy / 10#   0.6 Gy 
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EXPERIMENTAL DETERMINATION OF THE OPTIMUM MEANS 
OF COMBINING TOPOTECAN AND MIBG THERAPY IN THE 
TREATMENT OF NEUROBLASTOMA 
AG McCluskey*, RJ Mairs, M Boyd 
Department of Radiation Oncology, University of Glasgow, Cancer Research 
UK Beatson Labs, Glasgow 
Background: Targeted therapy, using radiolabelled meta-
iodobenzylguanidine ([
131I]mIBG) has been shown to cause favorable 
remissions in neuroblastoma patients when used as a single agent. Long-term 
cure remains elusive however, and the full potential of this therapy may only 
be realised when it is combined with other agents. Topotecan (TPT) is a 
topoisomerase I inhibitor which has been shown to be an effective single 
agent treatment of refractory neuroblastoma. It has also been shown to act as 
a radiosensitizer to ionising radiation in vitro. If administered at the 
appropriate times relative to [
131I]mIBG delivery topotecan could potentially 
improve effectiveness by two different mechanisms:- increased concentration 
of [
131I]mIBG in neuroblastoma cells and decreased ability to repair targeted 
radiation damage.  Laboratory studies are underway to investigate these 
effects to determine the most effective means of combining these two 
treatment modalities. 
Methods:  The effect of topotecan pretreatment on [
131I]mIBG uptake was 
studied in vitro using cultured neuroblastoma cells.  Parallel studies on NAT 
expression were studied using real-time RT-PCR on RNA isolated from pre-
treated cells and tumours of mice treated with TPT.  Also, the ability of TPT 
to potentiate radiation-induced toxicity of [
131I]mIBG in neuroblastoma cells, 
was examined by clonogenic assay performed on SKNBE(2c) cells exposed 
to topotecan and [
131I]mIBG simultaneously.  The effects of combination 
therapy on the DNA of neuroblastoma cells were examined by TUNEL and 
SCGE.  Finally, topoisomerase I levels were evaluated in the neuroblastoma 
cell lines SKNBE(2c), SKNSH, SKNMC and SHSY5Y. 
Results:  Cells pre-treated with TPT have shown a 3 fold increase in uptake 
of [
131I]mIBG compared to untreated cells.  Real-time RT-PCR indicates a 2-
fold increase in NAT gene expression. Isobologram analyses of preliminary 
radiosensitization experiments suggest that combined TPT and [
131I]mIBG 
therapy produces synergistic killing in neuroblastoma cells.  TUNEL and 
SCGE analyses of DNA strand breaks show an increase in double strand 
breaks in cells dosed with TPT and [
131I]mIBG in combination, relative to 
either untreated cells, or cells treated with either agent alone. Relative 
topoisomerase I levels in neuroblastoma cell lines were identified as follows: 
SKNBE(2c) - 2U/ul; SKNMC - 3.37U/ul;  SKNSH - 3.05U/ul; SHSY5Y - 
1.56U/ul. 
Conclusions:  These results are encouraging for the use of topotecan in 
combination with [
131I]mIBG in the treatment of neuroblastoma. 
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TOTAL SKIN ELECTRON TREATMENT FOR MYCOSIS 
FUNGOIDES ￿ CLINICAL OUTCOME OF A MODIFIED VERSION 
OF THE MANCHESTER ARCING BEAM TECHNIQUE. 
D. Wilson
*, N. Thorpe, P. Chung, A. Stevens, J.A. Mills, R. Grieve, S 
Colligan. 
Walsgrave NHS Trust, Clifford Bridge Road, Coventry CV2 2DX. UK. 
Introduction: Total Skin Electron (TSE) treatment is an effective treatment 
for Mycosis Fungoides (MF), with reported response rates of 70-90%. 
Several TSE techniques have been described, most requiring extensive linear 
accelerator or room modification. A modified version of the Manchester 
arcing beam TSE technique, using 6 MeV electrons from a standard Philips 
SL25 linear accelerator has been developed, in an attempt to improve the 
dose distribution observed with the Manchester Technique, where lateral 
d o s e  f a l l  o f  i s  a  p r o b l e m .  P a t i e n t s  w e r e  i n c l i n e d  a t  3 0
o to the horizontal 
during treatment, and the standard electron scattering foil was modified to 
further increase the angle of incidence of the beam. The prescribed dose was 
24 Gray in 12 fractions, treating 2 quadrants daily for 4 days per week, 
overall treament time being 3 weeks
1.
Method: Between March 1996 and November 2000, 20 patients with 
extensively pre-treated stage Ib ￿ IV MF (30% with stage IV disease) were 
treated using a modified version of the Manchester arcing beam TSE 
technique. Clinical data pertaining to response, time to progression and 
toxicity were obtained retrospectively from case notes. 
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￿ 15 years). Follow-up was for a minimum of 8 months, with a mean of 17 
months. Response data were available for 17 patients (85%). The overall 
response rate was 87.5% (25% complete response and 62.5% partial 
response). To date, 11 patients from the study cohort have died. Mean 
survival subsequent to TSE was 15.3 months. The mean time to progression 
was 4 months (range 7 weeks to 15 months ￿ with no sign of relapse to date 
in one patient after 15 months of follow-up). Residual disease after TSE was 
successfully treated with local radiotherapy and/or PUVA in all cases. 
Common sites of disease recurrence were the axillae (4 patients), upper arms 
(3), lower arms (3) and feet (3). Thus, common sites of relapse were areas 
known to receive a lower dose in dosimetry studies
1. 
Toxicity:  Two deaths occurred shortly after treatment (MRSA skin infection 
and septicaemia in 1 patient and hypostatic pneumonia in a second). All 
patients completed treatment once started, although in 2 patients it was 
necessary to interrupt treatment temporarily due to severe skin reaction. Data 
for skin reactions were available for a subset of 12 patients  ￿67% suffered 
WHO grade 3/4 toxicity and 17% Grade 2. 
Conclusion:  The modified arcing beam technique demonstrated a high 
palliative response rate (87.5%) in patients with extensively pre-treated 
disease. A short mean time to progression (4mo) and severe skin toxicity 
were observed. A Betatron electron source is under commission and is 
expected to give improved dosimetry and clinical outcome. 
References: 1. Chung P, Thorp NC, Wilson DC. Total Skin Electron 
Treatment for Mycosis Fungoides ￿ The Coventry Experience. 2001.Br J 
Cancer; 85(Suppl 1):70. 
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PROLIFERATIVE VILLONODULAR SYNOVITIS TREATED 
SUCCESSFULLY WITH CONSERVATIVE SURGERY AND 
EXTERNAL BEAM RADIOTHERAPY
S. Mawdsley*
1, R. Glynne-Jones
2, S. Cannon
3, T. Briggs
3 and S. Short
2.
1The 
Gray Cancer Institute & 
2Marie Curie Research Wing, Mount Vernon 
Hospital, Northwood, Middlesex HA6 2RN, UK.  
3The Royal National 
Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, UK. 
Introduction:  Proliferative villonodular synovitis (PVNS) is a rare 
proliferative disorder of the synovium, which most commonly affects the 
knee, hand, hip and foot joints.  The aetiology and cell of origin remains 
unclear and it is commonly regarded as a benign neoplasm associated with 
chronic inflammation.  Surgery is the mainstay of treatment but this can be 
difficult in aggressive or recurrent cases.  Severe loss of joint function may 
result or an amputation may be necessary.  Preserving function of the ankle 
joint can be particularly problematic.  This report describes a series of cases 
of PVNS of the ankle and foot treated successfully with conservative surgery 
and external beam radiotherapy. 
Methods:  Data was collected retrospectively on six patients, treated between 
1993 and 2000 at Mount Vernon Hospital.  All patients had lesions at the foot 
or ankle.  The median time to treatment following their initial presentation 
was 19.5 months.  External beam radiotherapy was delivered to a dose of 
35Gy in 20 fractions over 4 weeks.  In all cases parallel-opposed fields were 
used to encompass the whole joint and affected extra-articular tissue, as 
defined both clinically and on MRI/CT. Local control and functional ability 
were assessed for the group. 
Results:  At a median follow-up of 19 months, all six patients remained free 
from recurrent disease.  The treatment was well tolerated with minimal acute 
toxicity.  In two patients, in whom an amputation had been considered it was 
avoided.  In terms of joint function, all but one patient had good range of 
movement at the ankle and five patients were able to function without the use 
of walking aids.  Follow-up in this series however, was too short to comment 
on the long-term toxicity. 
Conclusion:  Effective local control can be achieved with conservative 
surgery followed by external beam radiotherapy in patients with PVNS of the 
ankle or foot, without significant loss of joint function.
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HORMONAL AGENTS ALTER THE RADIO-RESPONSIVENESS OF 
BREAST CANCER CELLS IN VITRO 
Clare Orridge*
1; David A.L. Morgan
2; Stewart G. Martin
1.
1Cancer Research UK Academic Unit of Clinical Oncology, University of 
Nottingham, UK.  
2Department of Clinical Oncology, Nottingham City 
Hospital NHS Trust, Nottingham, UK.  
In the UK, more than 38 000 new cases of breast cancer are diagnosed in 
women each year.  Many patients receive radiotherapy as part of primary 
loco-regional management.  The systemic treatment of breast cancer is often 
dependant on the oestrogen receptor (ER) status of the tumour, with a large 
proportion of ER-positive tumours being treated by endocrine therapy, such 
as Tamoxifen.  Previous findings (Paulsen et al, 1996) suggest that ER-
positive tumour cells treated with Tamoxifen are more resistant to radiation.  
Tamoxifen is an anti-oestrogenic agent, or SERM (Selective Estrogen 
Receptor Modulator).  This group of compounds bind to the ER and either 
inhibit the receptor or lead to its partial inactivation.  Tamoxifen competes 
with oestrogen and causes partial inactivation of the ER.  Faslodex (ICI-182 
780) is a ￿pure￿ anti-oestrogen that has recently been developed.  It both 
down-regulates and inhibits the receptor.  Here we report the radio-
responsiveness of ER+ve and ER-ve breast cancer cells following exposure 
to the anti-oestrogenic agents Tamoxifen and Faslodex. 
In vitro studies were carried out on MCF-7 (ER+ve) and MDA MB 231 (ER-
ve) breast tumour cell lines.  Cells were cultured in phenol red deficient, 
serum-free media to remove any possible influence of oestrogenic substances 
in the growth media.  MTS (proliferation) assays were carried out in the 
presence of Tamoxifen or Faslodex.  Radiation survival (clonogenic) assays 
were carried out on drug treated and control cells. 
Proliferation data indicates that ER-ve cells do not show a significant effect 
with either Tamoxifen or Faslodex, whereas ER+ve cells, as expected, exhibit 
decreased proliferation (greatest with Faslodex).  Preliminary results from 
clonogenic assays suggest that as with previous findings, Tamoxifen-treated 
ER+ve cells appear to be more resistant to radiation.  Faslodex however, 
seems to induce radiosensitisation.  
Our data suggests that ER+ve patients receiving radiotherapy should possibly 
delay starting Tamoxifen treatment.  However, patients treated with Faslodex 
who are exposed to radiotherapy may show an increased response.   
Experiments are ongoing to examine if normal cell radiosensitivity is also 
altered. 
Reference: Paulsen, G.H.U.; Strickert, T.; Marthinsen, A.B.L.; Lundgren S.  
1996.  Acta Oncologica, 35 (8), 1011. 
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INFORMATION GIVEN TO PATIENTS ABOUT ADVERSE 
EFFECTS OF RADIOTHERAPY: A SURVEY OF PATIENTS￿ VIEWS 
G.C. Barnett, P.A. Murray, Essex County Hospital, Colchester, UK. 
Objective: To evaluate the amount of information patients require about 
adverse effects of treatment before giving informed consent. 
Design: Structured interview survey of patient opinion. 
Setting: Clinical Oncology Department, District General Hospital, UK. 
Participants: 82 adult oncology patients prior to starting treatment with 
radiotherapy. 
Main outcome measures: The risks of mild, moderate and severe adverse 
effects which patients feel are significant and about which they should be 
informed prior to consenting to treatment. 
Results: The distribution of responses to the interview was large. For a mild 
side effect, 31% of patients would only want to be informed if there was at 
least a 50% chance of it occurring, while 28% of patients wanted to be 
informed even if the risk of the side effect was as small as 0.1%. For severe 
side effects, 16% of patients wanted to be informed if the risk was at least 
50%, while 44% wanted to be informed of a 0.1% risk. There was no 
association with sex, treatment intent (radical or palliative), patient age, 
social class or disease site. 
Conclusions: It is very difficult to predict how much information patients 
feel they need prior to giving informed consent. Information needs varied 
widely within our survey population. Therefore a patient-centred approach 
must involve tailoring information to individual patient requirements. 
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expression (<90% of tumour cell positivity) was observed in 73% of sections.  
Nuclear  -catenin expression was seen in 25% of cases.  There was a 
significant association between positive nuclear -catenin and both increased 
MMP-9 expression (20% tumour cell positive) and high microvessel counts 
(upper tertile) (p=0.013 and p=0.030, respectively).   Neither nuclear nor 
reduced overall -catenin expression was associated with stage, histology or 
grade of tumour or platelet count. Reduced overall -catenin expression and 
positive nuclear -catenin expression were prognostic on univariate analysis 
(p=0.045, p=0.0015 respectively). Independent prognostic factors were stage 
(p<0.001), reduced overall -catenin (p<0.001), microvessel count (p<0.001) 
and nuclear -catenin (p<0.001).  These results suggest that nuclear -catenin 
acts as a transcription factor up-regulating MMP-9 and as yet undetermined 
angiogenic growth factors facilitating tumour growth and invasion in 
NSCLC.  Secondarily, disruption of the E-cadherin/ -catenin complex as 
evidenced by the prognostic significance of reduced overall -catenin 
expression has a role in the pathogenesis of NSCLC. 
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PLEURODESIS FOR MALIGNANT PLEURAL EFFUSIONS (MPE): 
A META-ANALYSIS   
*R Agarwal MRCP
1 and Paul Shaw MRCP
2, 
1Institute of Cancer Research, 
Section of Medicine, Cotswold Road, Sutton, Surrey, SM2 5PT; 
2Sir Michael 
Sobell House, Churchill Hospital, Oxford. 
 
Aim: MPE is a common oncological problem, however despite numerous 
clinical trials there is a lack of consensus on the optimal method of 
pleurodesis in these patients. This is due to the small sample size of 
individual trials published so far and the lack of a comprehensive meta-
analysis of the available data. We therefore undertook a meta-analysis of 
pleurodesis in order to try and define the optimal technique for pleurodesis in 
patients with MPE. 
Method: A systematic review of the literature was performed using PubMed, 
Embase and the Cochrane 'Controlled clinical trials register' from 1980 to 
2000. The databases were searched for all articles containing 'pleurodesis' OR 
'malignant pleural effusion' as either a textword or subject heading. No other 
restrictions were imposed on the search strategy. In addition other relevant 
studies were identified from conference proceedings and by writing to 
authours of included studies. Only randomized studies of pleurodesis of MPE 
were included in the final meta-analysis. 
Results: A total of 33 randomized controlled clinical trials of pleurodesis 
were identified containing a total of 1318 patients. 4 trials addressed the 
necessity for a sclerosant for pleurodesis. On meta-analysis the odds ratio for 
successful pleurodesis was 3.86 (95% CI 1.9-7.9) in favour of the use of a 
sclerosant. Analysis of the 8 trials comparing the efficacy of talc for 
pleurodesis to all other sclerosants revealed an odds ratio of 4.73 (2.65-8.42) 
in favour of talc. Subgroup comparisons of talc with bleomycin and 
tetracycline were also consistent with this result. No excess mortality was 
seen on meta-analysis among patients treated with talc. Seven studies 
compared bleomycin and tetracycline (including doxycycline). On meta-
analysis no significant differences in efficacy or mortality among treated 
patients was observed. Meta-analysis of the comparative efficacy of medical 
versus surgical pleurodesis is in progress. 
Conclusion: The results of this meta-analysis show that talc is the most 
effective sclerosant for pleurodesis in MPE. In addition there is no evidence 
for excess mortality from the use of talc in these studies. Talc either 
insufflated or as a slurry should therefore be the sclerosant of choice in these 
patients. 
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THE TREATMENT OF LUNG CANCER IN THE ERA OF HAART 
Powles T
1, Hawkin R
2, Shah P
2, Cox S
1, Sarker D
1, Nelson M
3, Gazzard B
3 
and Bower M
1. 
Depts 
1HIV Medicine, 
2Respirology, 
3Medical Oncology, Chelsea and 
Westminster Hospital, London. 
 
197 patients with lung cancer have been managed at the Chealsea and 
Westminster Hospital between 1999 and 2001. These have included six HIV-
seropositive patients (5 male:1 female), which had advanced (stage IV) 
disease. The mean age was 44.2 yrs (range: 313-58). The median CD4 cell 
count at lung cancer diagnosis was 342 mm
-3 (range: 117-995), and the 
median viral load was 283 copies/ml (range: <50-30020). Five patients were 
on highly active anti-retroviral therapy (HAART) (see table). 
 
Gender Histology  Stage  Smoke  (PY)  Survival 
(yrs) 
Male Squamous  IV  60  0.7 
Male Adeno  IV  40  0.5+ 
Female SCLC  Ext  30  0.1 
Male Squamous  IV  30  0.2 
Male NSCLC*  IV  40  0.2 
Male Broncho-
alveolar 
IV Non  smoker  1.2+ 
*unclassified non small cell lung cancer, SCLC = small cell lung cancer, PY 
= pack years, Ext = extensive. 
 
All six patients were treated with platinum-based combination chemotherapy 
using the same protocols that are employed in the immunocompetent patients. 
The actuarial one-year overall survival is 25%, and there was no significant 
difference in overall survival compared to the non-HIV patients with lung 
cancer (log rank p=0.43). Lung cancer in HIV+ patients is not associated with 
advanced immunosuppression, and thus may be treated in the same fashion as 
in the general population with similar survival outcomes. 
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A SINGLE CENTRE EXPERIENCE OF CISPLATIN AND 
VINORELBINE IN STAGE IIIA-IV NON SMALL CELL LUNG 
CANCER, (NSCLC) 
J White*, H Glen, A Anthoney, N O’Rourke and D J Dunlop. 
Beatson Oncology Centre, North Glasgow University Hospitals NHS Trust, 
Glasgow, UK. 
Introduction:  Cisplatin combined with vinorelbine has become standard 
therapy for the management of locally advanced and metastatic NSCLC, 
(Kelly et al J Clin Oncol 2001. 19;3210-18).  As part of budget approval for 
the use of this regimen, clinicians performed a prospective audit of efficacy 
and morbidity outcomes. 
Methods: Data from the first 52 cases with stage IIIa- IV NSCLC diagnosed 
between 1999-2000, and treated on 2 sites within the Trust are presented here 
and further data collection is ongoing. Treatment consisted of cisplatin 
80mg/m
2 d 1 and vinorelbine 30mg/m
2 d1 and 8, every 21 days, for a 
maximum of six cycles. Patients with stage IIIa disease received 2-3 cycles 
and were then re-assessed for high dose palliative or radical radiotherapy. 
Some patients received cisplatin and vinorelbine as second line therapy after 
failure of 1
st line non-cisplatin based therapy. 
Results: The ECOG performance status of patients was 0 = 15.4%, 1 = 
53.8%,  2 = 17.3%, 3 = 5.8% and not recorded 7.7%. Stage distribution was 
2B = 5.8%, 3A = 5.8%, 3B = 42.3%, 4 = 34.6% and 13.5% not recorded.  
Significant WHO G3/4 toxicity occurred in 59.6% of cases and 
haematological g3/4 myelosuppression was complicated by neutropenic 
sepsis in 21.2% of patients.  17.3% of patients had dose reductions of one or 
other of the drugs.  D 8 vinorelbine was reduced or omitted in 63.5% of 
patients. Response rates are as follows; CR 1.9%, PR 30.8%, SD 23.1%, PD 
21.3%. The OR was thus  32.7%.  The median survival was 8.75 months.  
Conclusions:  These response rates and median survival are similar to other 
published studies.  However, in our population of patients, (mostly PS 1-2), 
significant g3/4 toxicities, particularly complicated neutropenia, but also 
neuropathy, prompted clinicians to decrease the doses of cisplatin and 
vinorelbine to 75mg/m
2 and 25mg/m
2 day 1 and 8, respectively. Further data 
will be presented. 
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A PROSPECTIVE FEASIBILITY ANALYSIS OF TWO DIFFERENT 
SCHEDULES OF THE VINORELBINE-CISPLATIN REGIMEN IN 
ADVANCED NON SMALL CELL LUNG CANCER.
Gebbia V* (1, 2), Borsellino N (2), Galetta D (3), Caruso M (4), Valenza R 
(5). 
1) Department of Experimental Oncology, University of Palermo ; 2) La 
Maddalena Clinic for Cancer, Palermo ; 3) Oncological Institute, Bari ; 4) 
Centro Catanese di Oncologia, Catania ; Oncological Hospital, Palermo, 
Italy. 
The vinorelbine-cisplatin (VNR-CDDP) regimen is considered among the 
"standard" treatments for advanced poor prognosis stage IIIB or stage IV non 
small cell lung cancer (NSCLC). However, the VNR-CDDP regimen is not 
unique since several different dosages and schedules have been developed by 
different investigators in different countries on the basis of clinical and 
toxicologic considerations. The classical schedule with cisplatin 100-120 
mg/m2 on day 1 plus VNR 25-30 mg/m2/week every 28 days accordingly to 
the SWOG and the French data is associated with significant hematological 
toxicity which results in treatment discontinuation in 12-23% of patients and 
a 30-35% reduction in dose-intensity. These events may negatively 
conditionate the clinical results of the regimen and give an underestimation of 
the activity the combinationwhile stressing toxicity.  
Based on these toxicologic considerations our group started a prospective 
phase III study comparing the classical schedule of CDDP 100 mg/m2 on day 
1 plus VNR 25 mg/m2/week every 28 days to the schedule of CDDP 80 
mg/m2 on day 1 plus VNR 30 mg/m2 on day 1+8 every 21 days. The latter 
schedule was associated with a >5% discontinuation rate, and with a > 90% 
dose-intensity. The main aim of the trials was the incidence of severe 
toxicity, rate of discontinuations, analysis of dose-intensity. Secondary end-
points were response rates, time to progression and overall survival. 
According to a 30% difference of events 100 patients had to be enrolled 
(50/arm). To date  64 patients eith stage IIIB-IV have been enrolled into the 
trial and randomized according to stage and performance status (PS 0-1 
versus 2). All enrolled patients had to fulfil standard inclusion criteria : age < 
70 years, ECOG PS 0-2, measurable disease according to WHO criteria, no 
major cardiovascular, infective, neurological, renal, or metabolic diseases; 
absence of CNS metastases. Interim analysis of available data has shown an 
excess of severe leukopenia (p=0.048), and treatment omissions (p=0.047) in 
the weekly VNR arm. These data, if confirmed, will cause a re-interpretration 
of toxicity data achieved in phase III trials reported in medical literature. 
Final data of toxicity and efficacy parameters are awaited. 
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AUDIT OF IN-PATIENT MIC CHEMOTHERAPY FOR 
INOPERABLE NON-SMALL CELL LUNG CANCER 
Giridharan S*, Lo N, Madhava K, Hartley A, Peake D, Rea D 
Cancer Centre, Queen Elizabeth Hospital, Birmingham. B15 2TH. 
Introduction: Chemotherapy has been shown in randomised clinical trials to 
improve overall survival (OS) in patients with inoperable non-small cell lung 
cancer (NSCLC). However, patients fulfilling the eligibility criteria for such 
trials are not representative of the whole NSCLC population and 
extrapolation of these results to older patients and those with poor WHO 
performance status (PS) may not be appropriate.  The aim of this audit was to 
assess the OS of a population treated with an in-patient multi-agent regime 
outside of a clinical trial.  
Methods: Consecutive patients with inoperable NSCLC receiving in-patient 
chemotherapy between 1/10/00 and 31/3/01 with the MIC regime (mitomycin 
6mg/m
2, ifosfamide 3g/ m
2 and cisplatin 50mg/ m
2 administered every 3 
weeks) were included.  Age, sex, PS, stage, number of courses, toxicity, 
radiotherapy details and OS were obtained from hospital, general practice and 
cancer registry records. 
Results: 72 patients were identified. At a median follow up of one year 26% 
of patients were alive. Median OS for all patients was 8.6 months (m). 
Median OS in patients aged > 70: 11.0m (n=24); aged <70: 7.0 months 
(n=48); PS 0 patients: 11.0m (n=22); PS 1: 9.4m (n=26); PS 2: 5.1m (n=11); 
PS 3: 3.5m (n=13). Patients also receiving high dose thoracic radiotherapy 
(40-50 Gy in 15 fractions): 12.0m (n=13). 
Conclusions: While the numbers in this study are small, the OS seen in > 70 
group suggests that the continued use of multi-agent chemotherapy in 
selected elderly patients is justified. The OS seen in PS2 patients is consistent 
with results from randomised trials showing symptomatic but no survival 
benefit. The poor results obtained in PS3 patients call into question the value 
of palliative chemotherapy in this group. Further randomised studies with 
quality of life endpoints are required to define the optimum management for 
patients in these subgroups. 
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MALIGNANT PLEURAL MESOTHELIOMA  (MPM) AT 
ABERDEEN ROYAL INFIRMARY, ABERDEEN, SCOTLAND: 
SURVIVAL AND PROGNOSTIC FACTORS 
Eliyaz Ahamed*, Marianne Nicolson, Donald Bissett, Keith Kerr and Joe 
Legge, on behalf on the Aberdeen Lung Cancer Group, Aberdeen Royal 
Infirmary, Aberdeen  AB25 2ZN Scotland
Object: In light of the increasing incidence and publication of prognostic 
factors
1, 2 for MPM, we have audited those prognostic factors and survival in 
patients diagnosed with MPM between Jan 1994 and Dec 2000 at Aberdeen 
Royal Infirmary, Scotland. 
Methods: A retrospective case note review of 78 patients (pts) with 
histological confirmation of MPM between Jan 1994 and December 2000. 
Results: Mean age of onset was 65 years (range 41 to 85 years) with a male 
to female ratio of 4:1. Asbestos exposure was known in 53 and 55 were 
smokers. Of pathological subtypes 64 were epithelial, 12 sarcomatoid and 
two were biphasic.71% had local disease while 28% had regional or distant 
disease. Four pts were treated with surgery, 23 with chemotherapy and 19 
patients received palliative radiotherapy. Thirty-two patients received no 
treatment. The median survival (MS) was 9 months (range 1 to 79 months). 
Women survived longer than men (11 months compared to 9 months). MS 
was reduced in pts older than 70 years (6 v/s 11 months) and in those with 
sarcomatoid mesothelioma (6 v/s 9 months) and it was also less in those with 
thrombocytosis (7 v/s 8.5), anaemia (5.5a v/s 9 months) and leucocytosis (8 
v/s 9). No significant difference was seen in other parameters.  LDH was 
elevated in only two patients. 
Conclusions: The MS was short but similar to that reported by other groups
3, 4.
Sarcomatoid epithelioma, thrombocytosis and anaemia were important 
prognostic factors in our survey. Only four pts had surgery and survival was 
6,7,9 and 56 months. Chemotherapy did not result in significant survival 
benefit over best supportive care (MS 9 months). Better therapies are 
required for this increasingly common and fatal disease. 
1 Curran  D  et al  J Clin Oncol 1998,16:145-152 
2 Herndon  JE  et al Chest 1998 113:723-731 
3  Adams VI Cancer 1986 58: 1540-1551 
4  Ruffie J Clin Oncol 1989 7:1157-1168 
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GENETIC INSTABILITY AND NEUROENDOCRINE PHENOTYPE 
IN BRONCHIAL CARCINOGENESIS: A CLINICAL STUDY 
Marta Ocejo-Garcia
1, Irshad Soomro
2, David R Baldwin
3, Judy M Coulson
1,4,
Penella J Woll
1.
1CRC Academic Unit of Clinical Oncology and Departments 
of
2Pathology and 
3Respiratory Medicine, Nottingham City Hospital, UK; 
4Department of Physiology, Human Anatomy and Cell Biology, University of 
Liverpool, UK. 
Lung cancer is believed to develop through the accumulation of genetic 
alterations. Deletions at 3p occur earlier than 8p and are frequent in both 
small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 
SCLC secretes multiple neuropeptides, which can act as autocrine growth 
factors for these cancers. Here we investigate whether the neuroendocrine 
phenotype is an early or late event in bronchial carcinogenesis. 
Materials and methods: Clinical samples were obtained from lung cancer 
patients at bronchoscopy (BR, N=10), post-mortem (PM, N=3) and surgery 
(S, N=12), comprising tumour and bronchial epithelium at 1cm and 4-5cm. 
Matched normal DNA was obtained from blood (BR) or normal lung (PM, 
S). DNA and RNA were extracted simultaneously with a Qiagen DNA/RNA 
kit.  Samples were analysed for LOH at 3p and 8p loci by radioactive (alpha 
32P) PCR and gel analysis. RT-PCR was used to detect expression of the 
neuropeptides gastrin-releasin peptide (GRP) and arginine vasopressin (AVP) 
using beta-actin as a control. Southern Blotting was carried out to increase 
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peptide expression relative to actin.  
Results: LOH analysis showed more genetic lesions in the tumour samples 
compared to the proximal bronchial epithelium (1cm) and none in the distant 
bronchial epithelium (4-5cm). Surgical samples proved to contain a number 
of normal cells since GRP was expressed in all surgical samples. GRP 
expression was increased in tumour samples in 3/3 SCLC patients, whereas 
7/8 NSCLC patients showed a decrease or total disappearance of GRP 
expression in the tumour. AVP was not detected in SCLC post-mortem 
samples, possibly due to its short half-life. AVP was only expressed in 1/20 
NSCLC. Interestingly, a further patient, diagnosed with SCLC 5 years before 
but with no histological evidence of tumour at the time of bronchoscopy, 
tested positive for both AVP and GRP. 
Discussion: These results show that samples of bronchial mucosa adjacent to 
a lung cancer show increasing genetic instability that recapitulates bronchial 
carcinogenesis. GRP is expressed in normal bronchial mucosa, but is 
increased in SCLC and reduced in NSCLC and in some proximal (1cm) 
samples. AVP was expressed in a small number of SCLC, but not in normal 
or NSCLC samples. Future work will investigate more patients including a 
wide range of tumour types to establish whether neuroendocrine changes 
occur in premalignant bronchial mucosa and may represent a target for 
chemoprevention. 
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ENHANCED  IN VITRO INVASIVENESS AND DRUG RESISTANCE 
IN A HUMAN LUNG CARCINOMA CELL LINE, DLKP, AFTER 
TREATMENT WITH MITOXANTRONE, 5-FLUOROURACIL, 
METHOTREXATE, BCNU, CISPLATIN OR CHLORAMBUCIL, AND 
ENHANCED DRUG RESISTANCE BUT NOT IN VITRO
INVASIVENESS WITH VP-16, VINCRISTINE, TAXOTERE OR 
CCNU
Yizheng Liang*, Susan McDonnell, Padraig Doolan and Martin Clynes 
National Institute for Cellular Biotechnology / National Cell and Tissue 
Culture Centre, Dublin City University, Glasnevin, Dublin 9, Ireland 
Multidrug resistance (MDR) and invasion / metastasis are two major causes 
of death for cancer patients. Following our previous paper (Liang et al., Eur. 
J. Cancer, 37: 1041-1052, 2001) which reported the effects of taxol and 
melphalan exposure on drug resistance and cell invasion in a human nasal 
carcinoma cell line, RPMI-2650, we expanded this study to other ten 
commonly used chemotherapeutic drugs (VP-16, vincristine, taxotere, 
mitoxantrone, 5-fluorouracil, methotrexate, CCNU, BCNU, cisplatin and 
chlorambucil) in a human lung squamous carcinoma cell line, DLKP, to 
investigate the impact of these drugs. The results of toxicity assays showed 
that all these drugs induced MDR; taxotere and mitoxantrone appeared to be 
able to induce higher level of MDR. Compared to the DLKP parental cell 
line, results of RT-PCR showed that mRNA expression of multidrug 
resistance proteins (MRPs), especially MRP3 and MRP5, was increased in 
various DLKP drug-resistant variants, along with the overexpression of P-
glycoprotein (Pgp) in the DLKP taxotere-resistant variant (DLKP-TXT) as 
well as breast cancer resistance protein (BCRP) in the DLKP mitoxantrone-
resistant variant (DLKP-MITOX). Western blot showed the overexpression 
of Pgp and MRP1 in DLKP-TXT. Results of invasion assays indicated that 
exposure to mitoxantrone, 5-fluorouracil, methotrexate, BCNU, cisplatin or 
chlorambucil made DLKP cells much more invasive in vitro while VP-16, 
vincristine, taxotere and CCNU were not able to induce the invasiveness of 
the DLKP cells. Gelatin zymography, Western blot and RT-PCR showed that 
DLKP and its variants secreted matrix metalloproteinase (MMP)-2, -9 and -
13. Results of the MMP inhibition assays indicated that MMP-2 played a 
much more important role than MMP-9 and -13 in DLKP cell invasion in
vitro, which may have implications for non-small-cell lung cancer (NSCLC) 
treatment. In conclusion, our results indicate that some effective anti-cancer 
drugs, especially non-direct-DNA-damaging drugs, do not promote cell 
invasiveness in vitro and could be safer in this regard than other ones, 
especially some of the alkylating agents, and this may have implications for 
drug design and drug treatment. 
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BRITISH THORACIC SOCIETY (BTS)  RANDOMIZED 
FEASIBILITY STUDY OF ACTIVE SYMPTOM CONTROL WITH 
OR WITHOUT CHEMOTHERAPY IN MALIGNANT PLEURAL 
MESOTHELIOMA 
W Qian
1, DJ Girling
1 and MF Muers
2 on behalf of all collaborators  
1MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA   
2General Infirmary, Leeds LS1 3EX 
Background:  The incidence of mesothelioma is rising rapidly in Britain.  
Annual deaths will rise from 1500 in the year 2000 to 3000 in 2020. There is 
no generally accepted standard treatment. The BTS recommends active 
symptom control  (ASC).  It is not known whether chemotherapy in addition 
prolongs survival or provides worthwhile palliation with acceptable toxicity.  
Palliation as recorded by patients has been reported for only 2 regimens: 
mitomycin, vinblastine, and cisplatin (MVP), and vinorelbine (N).  The BTS 
and Medical Research Council plan to conduct a phase III trial comparing 
ASC only, ASC + MVP, and ASC + N in 840 patients with survival as the 
primary endpoint.  The aim of the present study was to assess (1) the 
acceptability of the trial design to patients, and (2) the suitability of two 
standard quality of life (QL) questionnaires for mesothelioma.   
Methods:   Collaborating centres registered all new mesothelioma patients.  
Those with microscopically and immunohistochemically confirmed disease, 
any symptomatic pleural effusion under control, a CT scan in the previous 
month, fit for chemotherapy, and giving signed informed consent, completed 
EORTC QLQ-C30 + LC13 and FACT-L QL questionnaires, and were 
randomized between all three or any two of: (1) ASC only, (2) ASC + 4 
cycles of MVP, and (3) ASC + 12 weekly doses of N.  
Results:  During one year, 230 patients were registered of whom 109 (47%) 
were randomized, this being 59% of the 185 eligible patients.  52 from 20 
centers were randomized to an option including ASC only. This translates 
into a rate of 312 patients per year from 60 centers interested in collaborating 
in the phase III trial.  The EORTC  QL questionnaire was superior to FACT-
L in terms of completeness of data, patient preference, and clarity of 
definitions of categories.  
Conclusions:  The planned phase III trial is feasible and funding is being 
sought.  The EORTC QL questionnaire has been selected.  
Sponsors: The Jane Hancock and Anthony Farmer Mesothelioma Research 
Funds; Pierre Fabre Oncology; BTS. 
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A RETROSPECTIVE REVIEW OF TREATMENT OF  CERVICAL 
LYMPH NODE METASTASIS OF SQUAMOUS CELL CARCINOMA 
FROM AN UNKNOWN PRIMARY  
E Brown*, R Simcock, M O’Connell, F Calman, Guys and St.Thomas’ 
Cancer Centre, London, SE1 7EH, UK 
Introduction  Cervical lymph node metastasis of squamous cell carcinoma 
from an unknown primary (CUP) form 2-6% of head and neck cancers. 
Treatment of CUP is controversial and is to be the subject of an EORTC trial 
(24001-22005). In preparation for this trial we have reviewed our recent 
patient data.  
Methods  Patients were identified using departmental databases. Patients   
undergoing treatment with a diagnosis of CUP since 1995 were included. 
Presentations with Level V nodes excluded.  Case-notes were reviewed.  
Results 31 patients aged 50-79 (median 61.7) were identified with a median 
follow-up from completed treatment of 21.6 months . All patients had 
panendoscopy with mucosal biopsies and CT scans of the neck and chest. CT 
scanning changed the nodal staging in 4 patients. PET scanning was 
performed in 12 patients and provided additional information in 3 patients. In 
2 patients PET suggested possible primary sites (tonsil and nasopharynx) not 
confirmed on biopsy and in a third patient PET identified a separate NSCLC. 
19 patients were initially treated with a neck dissection and 2 patients 
required neck dissection for residual disease post radiotherapy. Radiotherapy 
was delivered with radical intent to both sides of the neck and potential 
mucosal primary sites in 90% of cases. The ipsilateral neck only was treated 
in 3 cases, in one case with palliative intent. Radical doses prescribed were 
60-64Gy in 2Gy daily fractions with electron boosts to residual disease  (15 
patients) . One patient one died of aspiration during treatment and a second 
repeatedly failed to attend, all others completed treatment. 6 required 
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died with a median of 4.5months from completing treatment. 4 patients 
developed local recurrence, one has been salvaged by surgery the remainder 
dying (median survival 15 months). One patient developed metastases and 
died 4 months after treatment. 2 patients developed an identified  primary 
head and neck cancer and one patient died of a metachronous NSCLC. Of the 
68% patients alive current disease free survival is 26.5 months. All surviving 
patients have reported xerostomia. 
Conclusions A policy of pan-mucosal radiotherapy for the majority of our 
patients with CUP has manageable toxicities and predictable morbidity with 
over 60% living to 2 years currently. PET scanning did not alter management 
in this group. The planned EORTC trial is needed to address the 
controversies over CTV and to provide quality of life data.
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THE ROLE OF SUPPORTIVE NUTRITION IN RADIOTHERAPY 
FOR ADVANCED CARCINOMA OF THE HEAD & NECK 
*E D Selvadurai and M E A O￿Connell 
Department of Clinical Oncology, Guy￿s & St Thomas￿ Hospital, London 
SE1 9RT, UK 
Introduction  
The treatment of advanced carcinoma of the head & neck is becoming more 
complex with combined modality ablative surgery and post-operative 
radiotherapy (SRT) and combination chemo/radiation therapy (CRT).   
Treatment breaks due to feeding difficulties adversely affect outcome by 
prolonging overall treatment time allowing tumour re-population resulting in 
reduced local control.  We studied retrospectively 49 consecutive patients 
with advanced carcinoma of the head & neck (stages III and IV) treated with 
radical intent to identify risk factors predictive of those patients requiring 
enteral nutrition (EN) so that this can be placed prior to RT. 
Patients & Methods 
Data on age, gender, performance status (PS), tumour site, ablative surgery, 
smoking, radiotherapy field arrangement and size, concomitant chemotherapy 
and weight loss were collected from the radiotherapy notes. 
Results 
There were 33 males and 16 females, ages 25 to 74 years (mean = 59).   
Patients were good PS, ECOG=0 (59%) and ECOG=1 (41%).  22 patients 
required EN: either a nasogastric tube alone (NG=8) or percutaneous 
endoscopic gastrostomy alone (PEG=8) during or immediately after radical 
radiotherapy.  Another 6 patients received NG first then a PEG.  49% of 
males required EN compared with 38% females.  54% of patients aged ≥ 60
required EN contrasted with only 35% of those aged <60.  84% of smokers 
required EN.  67% of patients requiring EN had tumours located in the oral 
cavity, oropharynx, nasopharynx and hypopharynx necessitating large 
opposed lateral radiation portals encompassing >50% of the oral cavity. 35% 
of surgical patients required EN, 86% of patients receiving concomitant 
chemotherapy required EN. 
Conclusions 
Factors predicting for significant weight loss requiring EN were: age ≥ 60,
male gender, significant amount of oral cavity and oropharynx in the 
radiation field, concomitant chemo/radiation therapy and continued smoking 
during radiotherapy.  We are developing an algorithm to determine when EN 
is likely to be required and ensure that this is in place prior to therapy thus 
avoiding undesirable treatment gaps. 
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CANCERS OF THE HEAD AND NECK: A NEW HIV-RELATED 
TUMOUR?
Powles T
1*, Powles J
2, Nelson M
3, Gazzard B
3, & Bower M
1
1Dept HIV Medicine, 
2Dept ENT Surgery, 
3Dept Medical Oncology. Chelsea 
and Westminster Hospital, London. 
Background: Highly active anti-retroviral therapy (HAART) has resulted in 
an increased life expectancy in people with HIV. Several solid tumours occur 
more frequently in HIV. The Epstein-Barr virus and the Human Papilloma 
virus have both been implicated in the pathogenesis of tumours of the head 
and neck (HNC), and therefore could be expected to occur at an increased 
frequency in HIV disease. We have examined the Chelsea and Westminster 
Hospital database between 1987 and 2001, and found 7 patients with head 
and neck tumours. 
Results:  The median age at presentation was 48 years (range 32-53). All 
seven were homosexual males and two had an AIDS defining diagnosis prior 
to their cancer. Six of the patients smoked cigarettes. The incidence of HNC 
was 1.7 (95% CI: 0.7-3.6) new cases per 10,000 patient years, compared to 
0.6 for the HIV-negative males. Treatment with radiotherapy or 
chemotherapy was poorly tolerated, with marked mucositis (grade 3-4) and a 
median fall in median CD4 cell count from 131 to 77 mm
-3. The median 
progression free survival was 7 months (range: 3-96+) and overall median 
survival was 27 months. Five of the seven patients died from progressive 
malignancy and one of HIV. 
Site of 
cancer 
Histopath. Stage  Nadir  CD4* 
(mm
-3)
Rx Survival 
(months) 
NP Anapl  T3N0M0  280  RT 17 
NP Undif  T2N2M0  347  RT  12 
LA Squam  T1N0M0  90  S  48 
LA Squam  T3N0M0 124  RT 27 
OC Squam  T2N0M0 250 S/RT  96+ 
OC Squam  T1N0M0 183  S  35 
OC Squam  T2N0M0  10  S  11 
*Prior to diagnosis of HNC. NP= nasopharyngeal, OC= oral cavity, LA= 
laryngeal, S= surgery, RT= radiotherapy. 
Conclusions: In this small series, HNC occurred more commonly in HIV 
patients compared to HIV negative individuals. The progression free and 
overall survivals were also markedly worse in the HIV patients. This may be 
due in part to the poor high toxicity (mucosal and immunological) of the 
treatment. 
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CHEMORADIATION IN ADVANCED HEAD AND NECK CANCER: 
HIGH SURVIVAL WITH INDUCTION CHEMOTHERAPY  
Martin, WMC*, Premachandra, DJ, Montgomery PQ et al for Norfolk and 
Waveney Head and Neck Cancer Group c/o Oncology Department, Norfolk 
and Norwich Hospital, Brunswick Road, Norwich   NR1 3SR 
PATIENTS AND METHODS: 54 patients with advanced squamous cancer 
of head and neck (HNSCC) were treated at Norfolk and Norwich Hospital 
between Dec 95 and Jan 01 by a policy of chemoradiation.  Inclusion criteria 
were patients with stage III ￿ IV or bulky stage 2 tumours, PS 0-1, in whom 
surgery to the primary would have involved major functional disability.   
Treatment consisted of induction with 2 or 3 cycles of cisplatin 100 mg/m
2
Day 1 with 5-fluorouracil 1000 mg/m
2 D2-6 (PF) followed by radiotherapy 
(RT) to primary and neck.  RT dosages were 66Gy/33F to primary tumour 
with spinal cord shielding after 40-44Gy, or 55Gy/20F for small fields, with 
50Gy/25F to uninvolved neck.   
Site - distribution was: tonsil 11, posterior tongue 11, other oropharynx 10, 
pyriform 7, supraglottis 12, glottis 2, floor of mouth 1.  Stage ￿ distribution 
was: II: 4 (7%), 3: 12 (22%), IVA: 24 (44%), IVB 14 (26%).  Patients were 
followed monthly for first year, q 2 months for second year, q 3 months third 
year, then 6-monthly, with 6-monthly CT from end of treatment.  Patients 
relapsing in the neck (n=3) underwent neck dissection and further adjuvant 
chemotherapy.  Of 4 patients relapsing at the primary site, 3 / 4 underwent 
radical surgery whereas 1 / 4 showed complete response to further PF 
chemotherapy.  All 7 remain disease free. 
RESULTS:  Overall survival at 1, 2, 3 and 5 years was 83%, 75%, 79% and 
100% respectively and disease - free survival 74%, 72%, 71% and 100% 
respectively (first 5 patients treated prior to January 1997 have 100% 
survival).   
Of 15 deaths 4 were associated with chemotoxicity.  All had N3 disease.  2/4 
were after first cycle, 2/4 after 2
nd cycle PF (one due to steroid associated 
perforation).  Other deaths were due to recurrence in primary (2), in neck (2), 
primary and neck (1), metastases (3), unrelated (3).  2 patients have 
developed second primary tumours.  2 patients are alive with metastases.   
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